Inflammatory bowel diseases, which include Crohn’s disease and ulcerative colitis, affect several million individuals worldwide. Crohn’s disease and ulcerative colitis are complex diseases that are heterogeneous at the clinical, immunological, molecular, genetic, and microbial levels. Individual contributing factors have been the focus of extensive research. As part of the Integrative Human Microbiome Project (HMP2 or iHMP), we followed 132 subjects for one year each to generate integrated longitudinal molecular profiles of host and microbial activity during disease (up to 24 time points each; in total 2,965 stool, biopsy, and blood specimens). Here we present the results, which provide a comprehensive view of functional dysbiosis in the gut microbiome during inflammatory bowel disease activity. We demonstrate a characteristic increase in facultative anaerobes at the expense of obligate anaerobes, as well as molecular disruptions in microbial transcription (for example, among clostridia), metabolite pools (acylcarnitines, bile acids, and short-chain fatty acids), and levels of antibodies in host serum. Periods of disease activity were also marked by increases in temporal variability, with characteristic taxonomic, functional, and biochemical shifts. Finally, integrative analysis identified microbial, biochemical, and host factors central to this dysregulation. The study’s infrastructure resources, results, and data, which are available through the Inflammatory Bowel Disease Multi’omics Database ( http://ibdmdb.org ), provide the most comprehensive description to date of host and microbial activities in inflammatory bowel diseases.

To the Editor: MetaPhlAn (metagenomic phylogenetic analysis) 1 is a method for characterizing the taxonomic profiles of whole-metagenome shotgun (WMS) samples that has been used successfully in large-scale microbial community studies 2,3 . This work complements the original species-level profiling method with a system for eukaryotic and viral quantitation, strain-level identification and strain tracking. These and other extensions make the MetaPhlAn2 computational package (http://segatalab. cibio.unitn.it/tools/metaphlan2/ and Supplementary Software) an efficient tool for mining WMS samples.Our method infers the presence and read coverage of cladespecific markers to unequivocally detect the taxonomic clades present in a microbiome sample and estimate their relative abundance 1 . MetaPhlAn2 includes an expanded set of ~1 million markers (184 ± 45 for each bacterial species) from >7,500 species (Supplementary Tables 1-3), based on the approximately tenfold increase in the number of sequenced genomes in the past 2 years. Subspecies markers enable strain-level analyses, and quasi-markers improve accuracy and allow the detection of viruses and eukaryotic microbes (a full list of additions is provided in Supplementary Notes 1-3 and Supplementary Fig. 1).We validated MetaPhlAn2 using 24 synthetic metagenomes comprising 656 million reads and 1,295 species (Supplementary Note 4 and Supplementary Table 4). MetaPhlAn2 proved more accurate (average correlation: 0.95 ± 0.05) than mOTU 4 and Kraken 5 (0.80 ± 0.21 and 0.75 ± 0.22, respectively) ( Fig. 1a, Supplementary Figs. 2-9 and Supplementary Tables 5-11),with fewer false positives (an average of 10, compared with 22 and 23 for mOTU and Kraken, respectively) and false negatives (an average of 12, compared with 27 for the other two methods), even when including genomes that were absent from the reference database (Supplementary Note 4). With the adoption of the BowTie2 fast mapper and support for parallelism, MetaPhlAn2 is more than ten times faster than MetaPhlAn, and its speed is comparable to that of other tested approaches ( Supplementary Fig. 10).We applied MetaPhlAn2 to four elbow-skin samples that we sequenced from three subjects (Fig. 1b, Supplementary Note 5 and Supplementary Table 12). Our data showed that Propionibacterium acnes and Staphylococcus epidermidis dominated these sites, in agreement with expected genus-level results 6 , while providing species-level resolution. Together with these core species, we found Malassezia globosa in 93.65% of samples and confirmed it by coverage analysis (Supplementary Fig. 11). Although M. globosa is a known colonizer of the skin, its metagenomic characterization highlights the ability of MetaPhlAn2 to identify non-prokaryotic species. Phages (e.g., for Propionibacterium) and double-stranded DNA viruses of the Polyomavirus genus were also consistently detected. We subsequently profiled the whole set of 982 samples from other body sites from the Human Microbiome Project (HMP), including 219 samples sequenced after the initi...

SUMMARY Just as reference genome sequences revolutionized human genetics, reference maps of interactome networks will be critical to fully understand genotype-phenotype relationships. Here, we describe a systematic map of ~14,000 high-quality human binary protein-protein interactions. At equal quality, this map is ~30% larger than what is available from small-scale studies published in the literature in the last few decades. While currently available information is highly biased and only covers a relatively small portion of the proteome, our systematic map appears strikingly more homogeneous, revealing a “broader” human interactome network than currently appreciated. The map also uncovers significant inter-connectivity between known and candidate cancer gene products, providing unbiased evidence for an expanded functional cancer landscape, while demonstrating how high quality interactome models will help “connect the dots” of the genomic revolution.

The inflammatory bowel diseases (IBD), which include Crohn’s disease (CD) and ulcerative colitis (UC), are multifactorial, chronic conditions of the gastrointestinal tract. While IBD has been associated with dramatic changes in the gut microbiota, changes in the gut metabolome -- the molecular interface between host and microbiota -- are less-well understood. To address this gap, we performed untargeted LC-MS metabolomic and shotgun metagenomic profiling of cross-sectional stool samples from discovery ( n =155) and validation ( n =65) cohorts of CD, UC, and non-IBD control subjects. Metabolomic and metagenomic profiles were broadly correlated with fecal calprotectin levels (a measure of gut inflammation). Across >8,000 measured metabolite features, we identified chemicals and chemical classes that were differentially abundant (DA) in IBD, including enrichments for sphingolipids and bile acids, and depletions for triacylglycerols and tetrapyrroles. While >50% of DA metabolite features were uncharacterized, many could be assigned putative roles through metabolomic “guilt-by-association” (covariation with known metabolites). DA species and functions from the metagenomic profiles reflected adaptation to oxidative stress in the IBD gut, and were individually consistent with previous findings. Integrating these data, however, we identified 122 robust associations between DA species and well-characterized DA metabolites, indicating possible mechanistic relationships that are perturbed in IBD. Finally, we found that metabolome- and metagenome-based classifiers of IBD status were highly accurate and, like the vast majority of individual trends, generalized well to the independent validation cohort. Our findings thus provide an improved understanding of perturbations of the microbiome-metabolome interface in IBD, including identification of many potential diagnostic and therapeutic targets.

Functional profiling from metagenomic or metatranscriptomic (“meta’omic”) sequencing provides insight into the molecular activities of microbial communities. These analyses are typically carried out using comprehensive search of sequencing reads, which is time-consuming, prone to spurious mapping, and often limited to community-level quantification. We developed a tiered meta’omic search strategy (HUMAnN2) which enables fast, accurate, and species-resolved functional profiling of host-associated and environmental communities. HUMAnN2 identifies a community’s known species, aligns reads to their pangenomes, performs translated search on unclassified reads, and finally quantifies gene families and pathways. Relative to pure translated search, HUMAnN2 is 3x faster and produces more accurate gene family profiles (89% vs. 67%). We apply HUMAnN2 to clinal variation in marine metabolism, ecological contribution patterns among human microbiome pathways, variation in species’ genomic vs. transcriptional contributions, and strain profiling. Finally, we introduce “contributional diversity” to explain patterns of ecological assembly across different microbial community types.

Summary The characterization of baseline microbial and functional diversity in the human microbiome has enabled studies of microbiome-related disease, microbial population diversity, biogeography, and molecular function. The NIH Human Microbiome Project (HMP) has provided one of the broadest such characterizations to date. Here, we introduce an expanded second phase of the study, abbreviated HMP1-II, comprising 1,631 new metagenomic samples (2,355 total) targeting diverse body sites with multiple time points in 265 individuals. We applied updated profiling and assembly methods to these data to provide new characterizations of microbiome personalization. Strain identification revealed distinct subspecies clades specific to body sites; it also quantified species with phylogenetic diversity under-represented in isolate genomes. Body-wide functional profiling classified pathways into universal, human-enriched, and body site-enriched subsets. Finally, temporal analysis decomposed microbial variation into rapidly variable, moderately variable, and stable subsets. This study furthers our knowledge of baseline human microbial diversity, thus enabling an understanding of personalized microbiome function and dynamics.

The gut microbiome plays a key role in human health. This community is dynamic during the first three years of life, before stabilizing to an adult-like state. However, relatively little is known about the impact of environmental factors on the developing human gut microbiome. Here we report a longitudinal study of the gut microbiome based on DNA sequence analysis of monthly stool samples and clinical information from 39 children, approximately half of whom received multiple courses of antibiotics during the first three years of life. While the gut microbiome of most vaginally born children was dominated by Bacteroides species, we found that all four children born by Cesarean section and approximately 20% of vaginally born children lacked Bacteroides in the first six to eighteen months. Our longitudinal sampling, coupled with whole-genome shotgun sequencing, allowed us to detect strain-level variation as well as the abundance of antibiotic resistance (AR) genes. The microbiota of antibiotic-treated children was less diverse at the level of both species and strains, with some species often dominated by single strains. In addition, we observed short-term composition changes between consecutive samples from children treated with antibiotics. AR genes carried on microbial chromosomes showed a strong peak in abundance after antibiotic treatment followed by a sharp decline, whereas some genes on mobile elements persisted longer after the end of antibiotic therapy. Our results highlight the value of dense longitudinal studies with high-resolution strain profiles in studying the establishment and response to perturbation of the infant gut microbiome.

Summary According to the hygiene hypothesis, the increasing incidence of autoimmune diseases in western countries may be explained by changes in early microbial exposure, leading to altered immune maturation. We followed gut microbiome development from birth until age three in 222 infants in Northern Europe, where early-onset autoimmune diseases are common in Finland and Estonia but less prevalent in Russia. We found that Bacteroides species are lowly abundant in Russians but dominate in Finnish and Estonian infants. Therefore their Lipopolysaccharide (LPS) exposures arose primarily from Bacteroides rather than from Escherichia coli which is a potent innate immune activator. We show that Bacteroides LPS is structurally distinct from E. coli LPS and inhibits innate immune signaling and endotoxin tolerance; furthermore, unlike LPS from E. coli, B. dorei LPS does not decrease incidence of autoimmune diabetes in non-obese diabetic mice. Early colonization by immunologically silencing microbiota may thus preclude aspects of immune education.